P1, N=9, Terminated, Taipei Medical University Shuang Ho Hospital | Trial completion date: Dec 2024 --> Mar 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Mar 2024; The overall profile does not support development for metastatic colorectal cancer

2 days ago

Trial completion date • Trial termination • Trial primary completion date • Metastases

KRAS (KRAS proto-oncogene GTPase)

KRAS mutation • RAS mutation • RAS wild-type

Epidaza (chidamide) • celecoxib oral

Photodynamic Therapy-Induced Immune Modulation: Part III (clinicaltrials.gov)

P1, N=12, Terminated, Wright State University | Completed --> Terminated; Per PI due to data analysis results.

3 days ago

Trial termination

celecoxib oral

13d

Treatment of cancer-associated fibroblast-like cells with celecoxib enhances the anti-cancer T helper 1/Treg responses in breast cancer. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)

Our study shows the important role of COX-2 in CAFs by promoting immune suppression. Our results suggested that high expression of COX-2 in CAFs may serve as a new therapeutic, targeting CAFs in enhancing immune responses in breast cancer treatment.

13 days ago

Journal

IFNG (Interferon, gamma) • IL10 (Interleukin 10) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • TGFB1 (Transforming Growth Factor Beta 1) • FOXP3 (Forkhead Box P3) • GATA3 (GATA binding protein 3) • IL4 (Interleukin 4)

IFNG expression • PTGS2 expression • FOXP3 expression

celecoxib oral

13d

Celecoxib for Prevention of Progression in Peutz-Jeghers Syndrome (clinicaltrials.gov)

P=N/A, N=80, Not yet recruiting, Air Force Military Medical University, China

13 days ago

New trial

celecoxib oral

13d

Serplulimab Combined with CAPEOX + Celecoxib As Neoadjuvant Treatment for Locally Advanced Rectal Cancer (clinicaltrials.gov)

P2, N=50, Recruiting, Zhejiang University | Trial completion date: Feb 2025 --> Dec 2025 | Trial primary completion date: Feb 2024 --> Dec 2025

13 days ago

Trial completion date • Trial primary completion date • Metastases

capecitabine • oxaliplatin • Hetronifly (serplulimab) • celecoxib oral

19d

Chrysanthemum indicum L. ameliorates muscle atrophy by improving glucose tolerance in CT26-induced cancer cachexia. (PubMed, Front Pharmacol)

After 1 week, the mice were orally administered vehicle, CI (100 mg/kg), or Celecoxib (50 mg/kg) for 3 weeks...Furthermore, we found that linarin, a constituent of CI, was responsible for the improvement of muscle atrophy. Our findings indicate that CI can ameliorate muscle atrophy by improving glucose uptake, suggesting that CI could be a therapeutic agent for cancer cachexia.

19 days ago

Journal

SLC2A4 (Solute Carrier Family 2 Member 4)

celecoxib oral

19d

99Tc-MDP Treatment for Knee Osteoarthritis (clinicaltrials.gov)

P=N/A, N=40, Recruiting, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025

19 days ago

Trial completion date • Trial primary completion date

celecoxib oral

20d

Deep learning-assisted colonoscopy images for prediction of mismatch repair deficiency in colorectal cancer. (PubMed, Surg Endosc)

The model achieved a high NPV in detecting deficient mismatch repair colorectal cancers. This model might serve as an automatic screening tool.

20 days ago

Journal • Mismatch repair • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker

MSI (Microsatellite instability)

MSI-H/dMMR

Loqtorzi (toripalimab-tpzi) • celecoxib oral

Stony Brook Medicine Anti-Inflammatory Trial (clinicaltrials.gov)

P4, N=42, Not yet recruiting, Stony Brook University

1 month ago

New P4 trial

celecoxib oral • minocycline

pH-Activatable Molecular Probe for COX-2 Imaging in Human Oral Squamous Carcinoma Cells and Patient-Derived Tissues. (PubMed, ACS Appl Bio Mater)

We have developed an SMPD, cyclooxygenase-2 (COX-2) targeting pH-activable fluorophore named CNP, combining a potent COX-2 inhibitor, celecoxib, linked to a naphthalimide fluorophore with an acidic microenvironment-responsive piperazine moiety for specific optical imaging of OSCC in cells and patient tissues...Further, CNP is demonstrated in imaging OSCC cells in patient-derived biopsies. Thus, multifunctional CNP shows potential in exploring more reagents for fluorescence-based detection of OSCC cells in patient tissues with translational applications.

1 month ago

Journal

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

PTGS2 expression

celecoxib oral

Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer. (PubMed, J Immunother Cancer)

Combined paclitaxel/CKM regimen was safe, with desirable TME changes and preliminary indications of promising pCR+ypTmic of 66%, comparable to the combination of NAC with pembrolizumab.

1 month ago

Journal

FOXP3 (Forkhead Box P3) • TLR3 (Toll Like Receptor 3) • IFNA1 (Interferon Alpha 1)

Keytruda (pembrolizumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Ampligen (rintatolimod) • celecoxib oral

INFLAMED: Treating Immuno-metabolic Depression With Anti-inflammatory Drugs (clinicaltrials.gov)

P3, N=140, Recruiting, Amsterdam UMC, location VUmc | Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Dec 2024 --> Jul 2025

1 month ago

Trial completion date • Trial primary completion date

IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)

celecoxib oral

The Effect of Celecoxib on Neuroinflammation in MDD (clinicaltrials.gov)

P4, N=42, Recruiting, Stony Brook University | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025

1 month ago

Trial completion date • Trial primary completion date

celecoxib oral

Perioperative propranolol and celecoxib (ProCel) in stage III melanoma (ACTRN12624001353583)

P2, N=40, Not yet recruiting, Sydney Local Health District

1 month ago

New P2 trial • IO biomarker • Immune cell

PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • B2M (Beta-2-microglobulin) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD163 (CD163 Molecule) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • ICOS (Inducible T Cell Costimulator) • SOX10 (SRY-Box 10) • CD14 (CD14 Molecule) • CD27 (CD27 Molecule) • VIM (Vimentin) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • HLA-E (Major Histocompatibility Complex, Class I, E) • CD31 (Platelet and endothelial cell adhesion molecule 1) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • FOXP3 (Forkhead Box P3) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • ITGAX (Integrin Subunit Alpha X) • MITF (Melanocyte Inducing Transcription Factor) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • CD1C (CD1c Molecule) • TCF7 (Transcription Factor 7) • CD3E (CD3 Epsilon Subunit Of T-Cell Receptor Complex) • S100B (S100 Calcium Binding Protein B)

celecoxib oral

INFINITE: Efficacy & Safety of RAd-IFN Administered with Celecoxib & Gemcitabine in Patients with Malignant Pleural Mesothelioma (clinicaltrials.gov)

P3, N=53, Active, not recruiting, Ferring Ventures Limited | Trial completion date: Nov 2024 --> Apr 2026 | Trial primary completion date: Nov 2023 --> Mar 2024

1 month ago

Trial completion date • Trial primary completion date • Combination therapy

MSLN (Mesothelin) • EFEMP1 (EGF Containing Fibulin Extracellular Matrix Protein 1)

gemcitabine • Adstiladrin (nadofaragene firadenovec-vncg) • celecoxib oral

2ms

Celecoxib for ENT Pain Management (clinicaltrials.gov)

P2, N=84, Recruiting, University of Wisconsin, Madison | Not yet recruiting --> Recruiting

2 months ago

Enrollment open

celecoxib oral

2ms

Cytobiological Alterations Induced by Celecoxib as an Anticancer Agent for Breast and Metastatic Breast Cancer. (PubMed, Adv Pharm Bull)

These mechanisms collectively hinder tumor growth, immune evasion, and metastatic spread. By synthesizing recent findings and analyzing the impact of celecoxib on these pathways, this paper seeks to delineate the integrated approaches necessary for managing metastatic breast cancer effectively.

2 months ago

Review • Journal • Metastases

HER-2 (Human epidermal growth factor receptor 2)

HER-2 positive • HR positive • HR positive + HER-2 positive

celecoxib oral

2ms

CARES for Kids: Comparing Analgesic Regimen Effectiveness and Safety for Surgery for Kids Trial (clinicaltrials.gov)

P4, N=900, Not yet recruiting, University of Michigan

2 months ago

New P4 trial • Surgery

celecoxib oral

2ms

Effect of Celecoxib on Postoperative Analgesia and Disease Severity in AERD Patients with CRS (clinicaltrials.gov)

P4, N=44, Active, not recruiting, Lawson Health Research Institute | Recruiting --> Active, not recruiting | Trial completion date: Apr 2025 --> Jul 2026 | Trial primary completion date: Feb 2025 --> Feb 2026

2 months ago

Enrollment closed • Trial completion date • Trial primary completion date

aspirin • celecoxib oral

2ms

Exploring the Structure-Activity Relationship of COX Inhibitors with Anticancer Effects: A Comprehensive Review. (PubMed, Curr Top Med Chem)

Additionally, several manuscripts employed well-known COX inhibitors, including licofelone, indomethacin, naproxen, tolfenamate, celecoxib, flumizole, and ketoprofen, as starting points for further derivatization and optimization...In particular, derivatives in studies 9, 16, and 24 demonstrated significant activity comparable to standard drugs like celecoxib and doxorubicin...This review highlights the potential of COX-2 selective inhibitors in anticancer drug development. The findings support the development of selective COX-2 inhibitors with diverse chemical structures as a promising strategy for cancer therapy.

2 months ago

Review • Journal

EGFR (Epidermal growth factor receptor)

doxorubicin hydrochloride • celecoxib oral

2ms

Design, synthesis, and evaluation of benzhydrylpiperazine-based novel dual COX-2/5-LOX inhibitors with anti-inflammatory and anti-cancer activity. (PubMed, RSC Med Chem)

Compound 9d with 4-Cl substitution at the terminal phenyl ring showed promising inhibition of COX-2 (IC50 = 0.25 ± 0.03 μM) and 5-LOX (IC50 = 7.87 ± 0.33 μM), outperforming the standards celecoxib (IC50 = 0.36 ± 0.023 μM) and zileuton (IC50 = 14.29 ± 0.173 μM), respectively...Interestingly, 9d effectively reduced pain by 55.78%, closely comparable to the 59.09% exhibited by the standard indomethacin, and was also devoid of GI, liver, kidney, and cardiac toxicity. Furthermore, 9d demonstrated anti-cancer potential against in vitro A549, COLO-205, and MIA-PA-CA-2 human cancer cell lines and an in vivo Drosophila cancer model. The pharmacokinetic investigations revealed that 9d has good oral absorption characteristics.

2 months ago

Journal

IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)

celecoxib oral

2ms

The methionine cycle and its cancer implications. (PubMed, Oncogene)

Accordingly, Celecoxib, a specific NR4A2 inhibitor, is a potentially powerful inhibitor of tumor growth at least in this specific model. Additionally, formaldehyde, from endogenous or exogenous sources, can directly regulate both SAM steady-state-levels and the one-carbon metabolism, with relevant implication in cancer progression. These recent scientific advancements have provided a deeper understanding of the molecular mechanisms involved in cancer development, and its potential therapeutic regulation.

2 months ago

Review • Journal

TP53 (Tumor protein P53) • NR4A2 (Nuclear Receptor Subfamily 4 Group A Member 2)

celecoxib oral

2ms

Leptin as a surrogate immune-metabolic marker to predict impact of anti-cachectic therapy: results of a prospective randomized trial in multiple solid tumors. (PubMed, ESMO Open)

Leptin is a reliable predictive marker for multitargeted anti-cachectic treatment outcomes. Thus, it can be an ideal candidate for monitoring and predicting the effects of anti-cachectic treatment and a surrogate marker of the immune-metabolic actions of the selected drugs.

2 months ago

Journal

LEP (Leptin)

megestrol • celecoxib oral

3ms

Repurposing celecoxib as adjuvant therapy in patients with Parkinsonian disease: a new therapeutic dawn: randomized controlled pilot study. (PubMed, Inflammopharmacology)

Celecoxib could be a promising adjuvant therapy in managing patients with PD.

3 months ago

Journal

TNFA (Tumor Necrosis Factor-Alpha) • TLR4 (Toll Like Receptor 4) • BDNF (Brain Derived Neurotrophic Factor)

celecoxib oral

3ms

Improving Skin Cancer Treatment by Dual Drug Co-Encapsulation into Liposomal Systems-An Integrated Approach towards Anticancer Synergism and Targeted Delivery. (PubMed, Pharmaceutics)

The combination of therapeutic agents such as doxorubicin, 5-fluorouracil, paclitaxel, cetuximab, celecoxib, curcumin, resveratrol, quercetin, bufalin, hispolon, ceramide, DNA, STAT3 siRNA, Bcl-xl siRNA, Aurora-A inhibitor XY-4, 1-Methyl-tryptophan, and cytosine-phosphate-guanosine anionic peptide led to increased and targeted anticancer effects, having relevant complementary effects as well, including antioxidant, anti-inflammatory, and immunomodulatory activities, all relevant in skin cancer pathophysiology. The substantial potential of co-loaded liposomal systems as highly promising for advancing skin cancer treatment is demonstrated.

3 months ago

Review • Journal

BCL2L1 (BCL2-like 1) • STAT3 (Signal Transducer And Activator Of Transcription 3)

Erbitux (cetuximab) • paclitaxel • 5-fluorouracil • doxorubicin hydrochloride • celecoxib oral

3ms

Identification of key genes and pathways involved in T-DM1-resistance in OE-19 esophageal cancer cells through bioinformatics analysis. (PubMed, Heliyon)

The docking results revealed that NSAIDs, including Diclofenac, Mefenamic acid, Celecoxib, Naproxen, and Etoricoxib, significantly suppress resistant cancer cells. Moreover, the possible role of NSAIDs in mitigating T-DM1 resistance presents an intriguing avenue for further investigation. This research contributes significantly to the field and establishes a basis for further research to enhance treatment efficacy for EC patients.

3 months ago

Journal

CXCL8 (Chemokine (C-X-C motif) ligand 8) • FAT1 (FAT atypical cadherin 1) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • IL17A (Interleukin 17A) • FSCN1 (Fascin Actin-Bundling Protein 1) • NRP1 (Neuropilin 1) • TAGLN (Transgelin) • CDH11 (Cadherin 11) • CDH17 (Cadherin 17) • CTGF (Connective tissue growth factor) • ITGA6 (Integrin, alpha 6) • ITGB5 (Integrin Subunit Beta 5) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)

Kadcyla (ado-trastuzumab emtansine) • celecoxib oral

3ms

Effects and Mechanisms of Celecoxib on Intracerebral Hemorrhage (clinicaltrials.gov)

P2, N=60, Recruiting, National Taiwan University Hospital | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Jul 2025 --> Jul 2027

3 months ago

Trial completion date • Trial primary completion date

celecoxib oral

3ms

Long-term characterisation of the relationship between change in depression severity and change in inflammatory markers following inflammation-stratified treatment with vortioxetine augmented with celecoxib or placebo. (PubMed, Brain Behav Immun)

The present analysis suggests for the first time a possible longer-term clinical benefit of celecoxib augmentation of vortioxetine in inflammation-associated MDD treatment. However, further research is needed to confirm the finding and to ascertain the reason for such a delayed effect. Furthermore, the trial suggests that TNF-α may have a stronger relationship with anti-inflammatory MDD treatment outcomes than hsCRP, and should be investigated further for potential predictive utility.

3 months ago

Journal

TNFA (Tumor Necrosis Factor-Alpha) • CRP (C-reactive protein)

celecoxib oral

4ms

A drug-drug interaction trial between AR882, fluconazole, carbamazepine, celecoxib, and sulfasalazine in healthy particpants (ACTRN12623001038684)

P1, N=54, Completed, Arthrosi Therapeutics Australia Pty, Ltd a subsidiary of Arthrosi Therapeutics, Inc | Recruiting --> Completed

4 months ago

Trial completion

CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9)

celecoxib oral

4ms

The joint protective function of live- and dead-Lactobacillus plantarum GKD7 on anterior cruciate ligament transection induces osteoarthritis. (PubMed, Aging (Albany NY))

Accordingly, our findings imply that the treatment of both GKD7-L and GKD7-D has chondroprotective and analgesic effects on the OA rat model, and that celecoxib and GKD7-L at dosages (100 mg/kg) have comparable therapeutic benefits. As a result, we propose that both GKD7-L and GKD7-D are helpful supplements for OA management.

4 months ago

Journal

TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • ACAN (Aggrecan) • MMP3 (Matrix metallopeptidase 3)

celecoxib oral

4ms

Individualizing Anti-Inflammatory Medications for Adults With Axial Spondyloarthritis: A Series of N-of 1 Trials (clinicaltrials.gov)

P2, N=42, Terminated, The University of Texas Health Science Center, Houston | Completed --> Terminated; lack of recruitment

4 months ago

Trial termination

celecoxib oral

4ms

ER-associated degradation ligase HRD1 links ER stress to DNA damage repair by modulating the activity of DNA-PKcs. (PubMed, Proc Natl Acad Sci U S A)

Both in vitro and in vivo cancer models showed that genetic or pharmacological inhibition of HADC1 or DNA-PKcs sensitizes colon cancer cells to ER stress inducers, including the Food and Drug Administration-approved drug celecoxib. The antitumor effects of the combined approach were also observed in patient-derived xenograft models. These findings identify a mechanistic link between ER stress (ERAD) in the cytoplasm and DNA damage (NHEJ) pathways in the nucleus, indicating that combined anticancer strategies may be developed that induce severe ER stress while simultaneously inhibiting KU70/KU80/DNA-PKcs-mediated NHEJ signaling.

4 months ago

Journal

HDAC1 (Histone Deacetylase 1)

celecoxib oral

4ms

Novel Celecoxib Derivative, RF26, Blocks Colon Cancer Cell Growth by Inhibiting PDE5, Activating cGMP/PKG Signaling, and Suppressing β-catenin-dependent Transcription. (PubMed, Anticancer Agents Med Chem)

Further evaluation of RF26 for the prevention or treatment of cancer and studying the role of PDE5 in tumorigenesis are warranted.

4 months ago

Journal

CTNNB1 (Catenin (cadherin-associated protein), beta 1)

sildenafil • celecoxib oral

4ms

Multitargeted molecular docking and dynamics simulation studies of 1,3,4-thiadiazoles synthesised from (R)-carvone against specific tumour protein markers: An In-silico study of two diastereoisomers. (PubMed, Comput Biol Chem)

However, the binding strength of 6c was found to be less than that of the standard drug, doxorubicin, as it formed lower conventional hydrogen bonds...However, the binding potential 3a was much lower than that of the standard COX-2 inhibitor, celecoxib...The DFT study showed that 3a had higher chemical stability than 6c. The electron exchange capacity, chemical stability, and molecular orbital distributions of the stereoisomers of the active compounds were also found to be alike.

4 months ago

Journal

CASP3 (Caspase 3)

doxorubicin hydrochloride • celecoxib oral

4ms

The dual role of CCND1 in heterotopic ossification: A Non-canonical Pathway for Celecoxib treatment. (PubMed, Heliyon)

In the process of treating heterotopic ossification with Celecoxib, immune and inflammatory signaling pathways play a significant role. The therapeutic effect of Celecoxib on heterotopic ossification depends on the hub gene CCND1, which plays different roles at different stages of the progression of heterotopic ossification, ultimately inhibiting the occurrence of heterotopic ossification.

4 months ago

Journal

CCND1 (Cyclin D1) • IL6 (Interleukin 6) • CDH1 (Cadherin 1) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • IGFBP3 (Insulin-like growth factor binding protein 3) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)

celecoxib oral

4ms

New pyrazole-pyridazine hybrids as selective COX-2 inhibitors: design, synthesis, molecular docking, in silico studies and investigation of their anti-inflammatory potential by evaluation of TNF-α, IL-6, PGE-2 and NO in LPS-induced RAW264.7 macrophages. (PubMed, RSC Med Chem)

Trimethoxy derivatives 5f and 6f were the most active candidates, demonstrating higher COX-2 inhibitory action than celecoxib, with IC50 values of 1.50 and 1.15 μM, respectively...Morover, according to the investigation using molecular modeling studies, derivatives 5f and 6f showed respectable binding affinity towards the COX-2 active site compared to the reference ligand. Moreover, the ADME parameters, physicochemical characteristics, pharmacokinetic characteristics, and l of the most potent compounds were also computed.

4 months ago

Journal

IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)

celecoxib oral

4ms

Porphyromonas gingivalis promotes the occurrence of esophageal squamous cell carcinoma via an inflammatory microenvironment (PubMed, Zhonghua Zhong Liu Za Zhi)

A total of 180 C57BL/6 mice were randomly divided into 6 groups, i.e. control group, P. gingivalis group, 4NQO group, 4NQO + P. gingivalis group, 4NQO + P. gingivalis + celecoxib group, and 4NQO + P. gingivalis + antibiotic cocktail (ABC, including metronidazole, neomycin, ampicillin, and vancomycin) group, with 30 mice in each group, using the random number table. P. gingivalis promotes the occurrence of esophageal squamous cell carcinoma in mice by inducing an inflammatory microenvironment primed with 4NQO induced DNA damage. Clearance of P. gingivalis with ABC or anti-inflammatory intervention holds promise for prevention of esophageal squamous cell malignant pathogenesis via blockage of IL-6/STAT3 signaling and amelioration of inflammation.

4 months ago

Journal

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)

celecoxib oral

5ms

Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines (clinicaltrials.gov)

P1/2, N=25, Recruiting, Roswell Park Cancer Institute | Suspended --> Recruiting

5 months ago

Enrollment open • Metastases

IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • CCL2 (Chemokine (C-C motif) ligand 2) • ITGAM (Integrin, alpha M) • FOXP3 (Forkhead Box P3) • CCL22 (C-C Motif Chemokine Ligand 22) • CCL3 (C-C Motif Chemokine Ligand 3) • ITGAX (Integrin Subunit Alpha X)

cisplatin • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral

5ms

Chemopreventive Effect of Combination of Celecoxib and Metformin in Patients With Familial Adenomatous Polyposis (clinicaltrials.gov)

P3, N=28, Recruiting, Yonsei University

5 months ago

New P3 trial

metformin • celecoxib oral

5ms

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (clinicaltrials.gov)

P2, N=24, Recruiting, Roswell Park Cancer Institute | Trial completion date: Aug 2025 --> Nov 2025 | Trial primary completion date: Aug 2025 --> Nov 2025

5 months ago

Trial completion date • Trial primary completion date • Combination therapy • IO biomarker

CD8 (cluster of differentiation 8)

Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral

5ms

Lumbrokinase Extracted from Earthworms Synergizes with Bevacizumab and Chemotherapeutics in Treating Non-Small Cell Lung Cancer by Targeted Inactivation of BPTF/VEGF and NF-κB/COX-2 Signaling. (PubMed, Biomolecules)

LPS-induced NF-κB activation reversed its inhibition on NSCLC cell proliferation and its synergy with chemotherapeutic cytotoxicity, while COX-2 inhibitor celecoxib treatment boosted such effects. Lumbrokinase combined with bevacizumab, paclitaxel, or vincristine inhibited the xenograft growth of NSCLC cells in mice more significantly than a single treatment. In conclusion, lumbrokinase inhibited NSCLC survival and sensitized NSCLC cells to bevacizumab or chemotherapeutics treatment by targeted down-regulation of BPTF/VEGF signaling and inactivation of NF-κB/COX-2 signaling, respectively. The combinational applications of lumbrokinase with bevacizumab or chemotherapeutics are expected to be developed as promising candidate therapeutic strategies to improve the efficacy of the original monotherapy in anti-NSCLC.

5 months ago

Journal

PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • BPTF (Bromodomain PHD Finger Transcription Factor)

Avastin (bevacizumab) • paclitaxel • vincristine • celecoxib oral